Iovance Biotherapeutics Inc

IOVA exhibits a parabolic continuation phase within a Stage 2 uptrend, with price now pulling back and tightly tracking above rising 9- and 21-day EMAs. Both medium- and short-term biases remain bullish, and current pullbacks offer a favorable entry around these EMAs. Execution should focus on buying pullbacks into the EMA zone with acceptance as confirmation, while a decisive break below the EMAs would invalidate the bullish stance.

• ↑Q2 revenue $99.3M (+66% YoY) fueled by Amtagvi uptake.
• ↑Gross margin hit all-time high 56%, up from 41% in Q1.
• ↓Weak profit margins persist despite R&D expense reductions.